Trung Huynh
Stock Analyst at UBS
(4.84)
# 85
Out of 5,111 analysts
56
Total ratings
73.68%
Success rate
33.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $741.29 | -10.97% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,027.51 | +5.11% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $197.01 | +13.19% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.77 | +1,312.43% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $317.74 | -0.23% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $27.51 | +38.13% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.85 | -3.29% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $52.41 | +3.03% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.36 | +196.61% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $8.78 | +48.06% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $211.58 | -17.29% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $100.30 | +25.62% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $223.32 | -23.88% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $9.14 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $741.29
Upside: -10.97%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,027.51
Upside: +5.11%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $197.01
Upside: +13.19%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.77
Upside: +1,312.43%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $317.74
Upside: -0.23%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $27.51
Upside: +38.13%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.85
Upside: -3.29%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $52.41
Upside: +3.03%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.36
Upside: +196.61%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $8.78
Upside: +48.06%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $211.58
Upside: -17.29%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $100.30
Upside: +25.62%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $223.32
Upside: -23.88%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $9.14
Upside: -